ByteDance, parent of short-video sensation TikTok, was set to conduct a share buyback this week that values it at $315 billion, a record for the company, according to Reuters.

Citing unnamed sources, Reuters reported on Wednesday that ByteDance informed its U.S. employees that it priced its latest share buyback offer at $189.90 per share. That represents an increase of about 11% compared to last year’s $171 and a 4.9% rise from the $181 per share it offered six months ago. The report said ByteDance’s valuation has largely recovered after taking a hit over threats of a U.S. TikTok ban.

Last year, the U.S. passed a law requiring ByteDance to sell TikTok’s U.S. operations by Jan. 19 this year or face a ban in the country, citing national security risk. However, after taking office in January, U.S. President Donald Trump postponed the enforcement of the ban by 75 days. TikTok currently has 170 million users in the U.S. and has attracted multiple potential bidders, including Reddit (RDDT.US) co-founder Alexis Ohanian and popular YouTube creator MrBeast (Jimmy Donaldson). But ByteDance has not indicated it intends to sell the TikTok U.S. operation.

By Lee Shih Ta

To subscribe to Bamboo Works weekly free newsletter, click here

Recent Articles

Illustration of Luckin and Costa coffee being tasted

Luckin Coffee eyes global leap as China’s Double 11 loses its luster

Luckin could be preparing a bid for Costa Coffee. What's driving this potential deal, and what are its chances for success? And this year's Double 11 festival looks like a dud, with most big e-commerce companies failing to publish any big numbers. What does the future hold for this fast-fading shopping fest?
So-Young runs cosmetic surgery clinics

Can So-Young find new youth in bricks and mortar?

The cosmetic surgery specialist’s top line is growing as it opens new ‘light medical aesthetic’ clinics, but its bottom line is sagging as its older platform business evaporates Key Takeaways:…
CSPC delivered lower nine-month revenues and profits

CSPC feels the pain from sweeping cuts in drug prices

The pharmaceutical giant is paying the price for its aggressively low bids in China’s centralized drug tenders, as it shifts its focus from traditional to novel drugs Key Takeaway: The…